Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: 2015

Transgene Reports First Quarter 2015 Financial Results

20150422 PR US Q1 2015

Published 22 April 2015
Categorized as 2015, Press release

Transgene Presents New Pre-Clinical Data at AACR on (i) the Combination of TG4010 with Immune Checkpoint Inhibitors; (ii) TG3003, an Anti-CD115 Monoclonal Antibody

20150421 AACR 2015_English

Published 21 April 2015
Categorized as 2015, Press release, TG3003, TG4010

Immune checkpoint inhibitors enhance benefits of modified vaccinia virus Ankara to improve survival in preclinical models of cancer

Poster TG4010-AACR 2015-KR Karola Rittner, et al. AACR Annual Meeting, Philadelphia, PA, USA, 18-22 April 2015, Abst. 2497 Download the posterhere Poster Presentation

Published 21 April 2015
Categorized as -others, 2015, Publication, TG4010

The MVA viral platform for the treatment of cancer and chronic infectious diseases: Clinical experience from four randomized controlled phase II studies

Poster MVA VIRAL PLATFORM-AACR 2015-JML Jean-Marc Limacher, et al. AACR Annual Meeting, Philadelphia, PA, USA, 18-22 April 2015, Abst. 2498. Download the poster here Poster Presentation

Published 21 April 2015
Categorized as -others, 2015, Publication, TG4010

Agreement with FDA Announced for Special Protocol Assessment for Upcoming Phase 3 Pexa-Vec Trial in Advanced Liver Cancer

20150416 SPA release version EN clean

Published 16 April 2015
Categorized as 2015, Pexa-Vec, Press release

Transgene Reports 2014 Financial Results and Outlines Promising Clinical Pipeline (webcast)

20150324 FY results 2014 full release_ENG FINAL

Published 24 March 2015
Categorized as 2015, Press release

Transgene Announces New Pre-Clinical Data with TG4010 in Combination with Immune Checkpoint Inhibitors and TG3003 (humanized mAb anti-CD115) to be Presented at AACR

18032015_AACR 2015 curtain raiser_EN

Published 19 March 2015
Categorized as 2015, Press release, TG3003, TG4010

Viral hepatitis: HBV cure—can we pin our hopes on immunotherapy ?

Hung-Chih Yang, et al. Nature Reviews Gastroenterology & Hepatology (2015) doi:10.1038/nrgastro.2015.8 – Download the article Publication

Published 5 February 2015
Categorized as -others, 2015, Publication, TG1050

Transgene Announces Financial Calendar for 2015

20150107 PR 2015 financial calendar_EN_ver 1

Published 8 January 2015
Categorized as 2015, Press release

Posts pagination

Newer posts Page 1 … Page 3
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu